GENE ONLINE|News &
Eli Lilly, Lycia Partnership Signifies the Growing Targeted Protein Degradation Market
On August 25th, South San Francisco-based startup Lycia Therapeutics entered a multi-year collaboration with Eli Lilly to discover, develop and commercialize novel targeted therapeutics using the former's proprietary protein degradation technology.
As per the agreement, Lilly will pay Lycia $35 million in an upfront payment. In addition, Lycia is also eligible to receive over $1.6 billion in potential milestone payments as well as tiered royalties from mid-single to low double-digits on sales.
As per the agreement, Lilly will pay Lycia $35 million in an upfront payment. In addition, Lycia is also eligible to receive over $1.6 billion in potential milestone payments as well as tiered royalties from mid-single to low double-digits on sales.
GO Prime with only $1.49 now
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
